Cox proportional hazard ratios. by Bryan S. Margulies (21492667)

“…<i>In vitro</i> results demonstrated that MBC-005 mediated its anti-tumorigenic effect through a p21-dependent mechanism via a novel molecular pathway, in which N-allyl noroxymorphone component of MBC-005 stimulated the opioid growth factor receptor to increase p21 expression. Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. …”

Bioluminescent Doubling Time. by Bryan S. Margulies (21492667)

“…<i>In vitro</i> results demonstrated that MBC-005 mediated its anti-tumorigenic effect through a p21-dependent mechanism via a novel molecular pathway, in which N-allyl noroxymorphone component of MBC-005 stimulated the opioid growth factor receptor to increase p21 expression. Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. …”

Study Design. by Bryan S. Margulies (21492667)

“…<i>In vitro</i> results demonstrated that MBC-005 mediated its anti-tumorigenic effect through a p21-dependent mechanism via a novel molecular pathway, in which N-allyl noroxymorphone component of MBC-005 stimulated the opioid growth factor receptor to increase p21 expression. Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. …”

Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

“…The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…”

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

“…The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…”

The model in which the PoFbx23 is required in activating PoAce1 to control the expression of target genes. by Zhongjiao Liu (11877464)

Subjects:

Data that underlies the TAP-MS of three Ace1-TAP samples. by Zhongjiao Liu (11877464)

Subjects:

Data that underlies the ChIP-qPCR in this paper. by Zhongjiao Liu (11877464)

Subjects:

The top proteins interacting with PoAce1 identified through TAP-MS. by Zhongjiao Liu (11877464)

Subjects:

Ubiquitination of PoAce1 and effect of proteasome inhibitor MG132 on PoAce1. by Zhongjiao Liu (11877464)

Subjects:

The result of TAP-MS using PoAce1 as the bait. by Zhongjiao Liu (11877464)

Subjects:

The interaction between PoFbx23A and PoAce1. by Zhongjiao Liu (11877464)

Subjects:

The phenotype of the Δ<i>ace1</i> and (hemi)cellulase production of various mutants. by Zhongjiao Liu (11877464)

Subjects:

Subcellular localization of PoFbx23A and PoAce1. by Zhongjiao Liu (11877464)

Subjects:

PoAce1 enrichment in the specific regions of (hemi)cellulase genes assayed by ChIP-qPCR. by Zhongjiao Liu (11877464)

Subjects:

Saturation analysis of transcriptome data for the WT and Δ<i>fbx23</i>. by Zhongjiao Liu (11877464)

Subjects:

Construction strategies for GFP strains Ace1/Fbx23-GFP and BiFC strain Ace1-YFP-Fbx23. by Zhongjiao Liu (11877464)

Subjects:

Construction strategy and verification of strains Ace1/Fbx23-TAP, Δ<i>fbx23</i>, and Re<i>fbx23</i>. by Zhongjiao Liu (11877464)

Subjects:

Strains used in this study. by Zhongjiao Liu (11877464)

Subjects:

Phylogenetic and domain architecture analysis of PoAce1 orthologs. by Zhongjiao Liu (11877464)

Subjects: